Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib with Gemcitabine and Doxorubicin in Urothelial Cancer
NCT02420847Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2015; status: active, not recruiting.
02
Drugs
ixazomib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02420847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02420847.